Many people around the world are affected by cancer and autoimmune disease, and while we have made progress in treating these conditions, there is still a lot of work to do. Current treatments may stop working over time, do not work for everyone, or can cause difficult side effects. Our aim is to find new and improved treatments to help patients live better lives. We are focused on a novel approach to treating disease called targeted protein degradation, or TPD.
What is targeted protein degradation?
Many diseases happen because certain proteins in our bodies are not working the way they should. Most available medicines try to stop these proteins from causing problems. Our approach is different – we aim to remove these problem-causing proteins altogether. Nurix’s approach, TPD:
Works with your body’s natural way of removing old or damaged proteins
Has shown potential to treat diseases that have been historically difficult to treat
Could lead to treatments that last longer and have fewer side effects
May help people who haven’t found success with other treatments
Understanding clinical trials
We are testing our investigational drugs carefully through clinical trials, which are highly regulated research studies that help us establish that our drugs are safe and effective.
Clinical trials are a crucial step in bringing innovative therapies to patients. Clinical trials advance medical knowledge and patient care, have specific eligibility criteria, and have rules that ensure participation is voluntary.
Every person’s health situation is unique, so always talk to your doctor about what treatment options are best for you.
Our clinical trials
Bexobrutideg (NX-5948)
Relapsed / Refractory Chronic Lymphocytic Leukemia
Phase 2
Relapsed / Refractory Chronic Lymphocytic Leukemia
Status
Currently accepting new patients
What is NX-5948?
NX-5948 is an experimental drug that may help overcome relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is taken by mouth as a pill.
Who can join this study?
This study might be right for you if:
- You are an adult with confirmed relapsed/refractory CLL/SLL
- You have previously received both a BTK inhibitor and a BCL-2 inhibitor for treatment
Is this study right for me?
Joining a clinical trial is an important decision. Talk to your doctor about whether this study may be a good option for you. If you are interested in learning more, ask your doctor about this trial.
United Kingdom
Poland
France
United States
Bexobrutideg (NX-5948)
Relapsed / Refractory B-cell Malignancies
Phase 1A/1B
Relapsed / Refractory B-cell Malignancies
Status
Currently accepting new patients who meet eligibility criteria.
What is Bexobrutideg (NX-5948)?
Bexobrutideg is an experimental drug that may help overcome certain blood cancers. It’s taken by mouth as a pill.
Who can join this study?
This study might be right for you if:
- You are an adult with one of these B-cell cancers
- Chronic lymphocytic leukemia (CLL)
- Small lymphocytic lymphoma (SLL)
- Diffuse large B-cell lymphoma (DLBCL)
- Mantle cell lymphoma (MCL)
- Waldenström macroglobulinemia (WM)
- Marginal zone lymphoma (MZL)
- Follicular lymphoma (FL)
- Primary central nervous system lymphoma (PCNSL)
- You have already tried at least two other treatments for your cancer (or at least 1 prior therapy for patients with PCNSL)
- Your doctor believes standard treatments are unlikely to help you
Is this study right for me?
Joining a clinical trial is an important decision. Talk to your doctor about whether this study may be a good option for you. If you’re interested in learning more, ask your doctor about this trial.
United States
Netherlands
Poland
Spain
United Kingdom
France
Italy
Switzerland
Zelebrudomide (NX-2127)
Relapsed / Refractory B-cell Malignancies
Phase 1A/1B
Relapsed / Refractory B-cell Malignancies
Status
Currently accepting new patients who meet eligibility criteria.
What is NX-2127?
NX-2127 is an experimental drug that may help overcome certain blood cancers. It’s taken by mouth as a pill.
Who can join this study?
This study might be right for you if:
- You are an adult with one of these B-cell cancers
- Chronic lymphocytic leukemia (CLL)
- Small lymphocytic lymphoma (SLL)
- Diffuse large B-cell lymphoma (DLBCL)
- Mantle cell lymphoma (MCL)
- Waldenström macroglobulinemia (WM)
- Marginal zone lymphoma (MZL)
- Follicular lymphoma (FL)
- Primary central nervous system lymphoma (PCNSL)
- You have already tried at least two other treatments for your cancer (or at least 1 prior therapy for patients with PCNSL)
- Your doctor believes standard treatments are unlikely to help you
Is this study right for me?
Joining a clinical trial is an important decision. Talk to your doctor about whether this study may be a good option for you. If you’re interested in learning more, ask your doctor about this trial.
United States
NX-1607
Advanced Malignancies
Phase 1A/1B
Advanced Malignancies
Status
Currently accepting new patients who meet eligibility criteria.
What is NX-1607?
NX-1607 is an experimental drug that may help overcome certain advanced tumors. It’s taken by mouth as a pill.
Who can join this study?
This study might be right for you if:
- You are an adult with one of these cancers
- Platinum-resistant epithelial ovarian cancer (EOC)
- Gastric/gastroesophageal junction (GEJ) cancer
- Squamous cell carcinoma of the head and neck (HNSCC)
- Recurrent and either metastatic or unresectable melanoma
- Non-small cell lunger cancer (NSCLC)
- Metastatic castration-resistant prostate cancer (mCRPC)
- Malignant pleural mesothelioma (MPM)
- Triple-negative breast cancer (TNBC)
- Locally advanced or metastatic urothelial cancer
- Cervical cancer
- Microsatellite stable colorectal cancer (MSS CRC)
- Diffuse large cell B-cell lymphoma (DLBCL), including patients with Richter transformation (DLBCL-RT)
- Your doctor believes standard treatments are unlikely to help you
Is this study right for me?
Joining a clinical trial is an important decision. Talk to your doctor about whether this study may be a good option for you. If you’re interested in learning more, ask your doctor about this trial.
United States
United Kingdom
Expanded access
Nurix is committed to gaining regulatory approvals to make our medicines available broadly to patients as quickly as possible. We believe this approach will best serve patients who could benefit from our therapies.
Expanded access programs, also known as “pre-approval access” or “compassionate use,” may provide a pathway for patients with serious or life-threatening conditions to receive investigational drugs outside of clinical trials.
For detailed information about our expanded access policy for NX-5948, one of our investigational medicines, click here.
Advocacy resources
At Nurix, our partnership with patient advocacy groups is crucial in deepening our understanding of patients and their needs. Patient organizations are vital in guiding, supporting, and assisting patients. By engaging with these organizations, we gain essential knowledge that drives the development of new medicines and enhances the quality of information we provide.
Our commitment to sharing in the patient journey and learning from every interaction empowers us to better serve patients and create impactful solutions. We are dedicated to using these insights to make a meaningful difference in patient care and treatment.